A promising new approach for the gene therapy of cancer is the introduction of the herpes simplex virus thymidine kinase (HSV tk) gene into tumour cells, where the HSV tk gene product converts the nontoxic prodrug ganciclovir (GCV) into its cytotoxic metabolite. We constructed a recombinant plasmid containing the HSV tk gene using standard molecular biology techniques in order to investigate whether the HSV tk/GCV enzyme/prodrug system could kill the human nasopharyngeal carcinoma cell line HNE-1. The recombinant plasmid pcDNA3.1(-) CMV.TK was transfected into the HNE-1 cells by electroporation. The expression of HSV tk by the transfected HNE-1/TK cells was confirmed by mRNA amplification and Western blotting. The growth of HNE-1/TK cells was inhibited by GCV in a dosedependent manner. The HSV tk/GCV system also demonstrated a considerable bystander effect on co-cultured wild type HNE-1 cells. We conclude that the HSV tk/GCV system could be used as gene therapy for nasopharyngeal carcinoma.
Introduction
Suicide gene therapy has become one of the most promising areas of research in recent years. Suicide genes, combined with an appropriate vector, have been introduced into target cells where they produce a gene product that converts a harmless prodrug into a cytotoxic metabolite. The other mechanism of killing cells is known as the bystander effect, 1,2 whereby a toxic metabolite produced by transfected cells is transferred to the surrounding nontransfected cells, resulting in their death.
The herpes simplex virus thymidine kinase (HSV tk) gene product modifies ganciclovir (GCV), a guanosine analogue, to an intermediate metabolite that disrupts DNA synthesis. Moolten et al., 3 Nasopharyngeal carcinoma is rare in Western countries, but it is very common in southern China where it presents a serious health problem with an incidence of around 10 -20 per 100 000 people/year. 4 The use of suicide gene therapy with the HSV tk gene product in a nasopharyngeal carcinoma cell line, HNE-1, has not been reported previously in China. As a result, we constructed a recombinant plasmid containing the HSV tk gene to investigate the efficacy of this gene therapy approach in the treatment of nasopharyngeal carcinoma. 
Materials and methods

CELL CULTURE
CONSTRUCTION OF THE PLASMID VECTOR
A pair of primers based on the cDNA of the HSV tk gene (register number: 243488) were designed with an XhoI site at the 5´ flanking region of the upstream primer and a HindIII site into 5´ flanking region of the downstream primer: upstream primer: 5´-AAC TCGAGATGCJCTTCGTACCC-3´; downstream primer: 5´-ACAAGCTTTCAGTTAGCCTCCCC CA-3´.
A 1152 base pair (bp) fragment encoding HSV tk was amplified from plasmid PGEM-TK using the primers described above. The target gene fragment was then inserted positively into plasmid pcDNA3.1(-)CMV (Xiangya Molecular Research Laboratory, Changsha, China) by digestion with restriction endonucleases XhoI and HindIII to yield the recombinant plasmid pcDNA3.1(-)CMV.TK, the sequence of which was verified by further restriction endonuclease digestion and automatic cDNA sequencing analysis.
CELL TRANSFECTION
Blank plasmid pcDNA3.1(-)CMV without the HSV tk gene and the HSV tk genecontaining recombinant plasmid pcDNA3.1(-)CMV.TK were transfected separately into HNE-1 cells by electroporation. The transfected cells were selected for their resistance to the agent geneticin (G418), which indicated that they contained the plasmid, by culture in medium containing G418 (600 mg/l) for 2 weeks. G418-resistance cell clones, HNE-1/(-) (control cells without the HSV tk gene) and HNE-1/TK, were selected and expanded in cell culture.
EXPRESSION OF THE HSV TK GENE IN TRANSFECTED HNE-1 CELLS
Total RNA was extracted from 1.0 × 10 7 transfected cells using Trizole reagent (Gibco BRL). The reverse transcriptase-polymerase chain reaction (RT-PCR) was used to demonstrate the expression of HSV tk using the following primers: upstream primer, 5´-AATCGCGAACATCTACACCA-3´; downstream primer: 5´-CCAGCATAGCCAGGTCAA-3´.
Western blotting was used to detect the expression of HSV tk protein in the transfected HNE-1 cells. The HNE-1/TK cells were harvested, counted and lysed in 2 × Y Tang, J Li, S Zhao et al. Suicide gene therapy in nasopharyngeal carcinoma cells loading buffer (50 mM Tris-HCl pH 7.5; 150 mM NaCl; 5 mM ethylenediaminetetraacetic acid; 1 mM dithiothreonine; 1% Triton X-100) and incubated for 5 min at 99 °C. Cell extracts from wild type HNE-1 cells served as a negative control. Cell extracts were applied to a 10% sodium dodecyl sulphate polyacrylamide gel for electrophoresis (SDS-PAGE), followed by transfer to a poly(vinylidene fluoride) membrane using standard procedures. Western blots were probed with a primary mouse monoclonal antibody to human HSV tk protein (QED Bioscience Inc., San Diego, CA, USA) and a rabbit anti-mouse IgG antibody (Sigma) was used as the secondary antibody. Hybridization was visualized using an enhanced chemiluminescence detection system (ICN, Costa Mesa, CA, USA).
IN VITRO CYTOTOXICITY ASSAYS
Transfected HNE-1/TK and HNE1/(-) were used when in their logarithmic growth phase (i.e. when the cell culture was around 90% confluent). A total of 2 × 10 4 cells of each cell culture were inoculated into each well of a 96-well plate. After further culture for 24 h in an environment containing 5% CO 2 at 37 °C, different concentrations of GCV (0.5, 5, 50, 250 and 500 mg/l) were added to each well and the cells were cultured for a further 96 h. At the end of the culture period, 20 µl (5 g/l) of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl-2H-tetrazolium bromide] was added to each well and the cells were cultured for 4 h. The cell culture medium was removed from each well and 100 µl dimethyl sulfoxide was added. The cells were kept at 37°C for 30 min. The relative cell survival rate was calculated using the absorbance (A) value obtained by measuring the optical density (OD) at 560 nm (Bio-Rad model 3550; Bio-Rad Laboratories, Hercules, CA, USA). Relative cell survival according to the dose of GCV was calculated to show the cytotoxic effect of pcDNA3.1(-)CMV.TK/GCV on HNE-1 cells using the following formula:
Relative cell survival rate (%) = A for the experimental group × 100
A for the control group
BYSTANDER EFFECT OF HSV TK MEASURED BY THE MTT ASSAY
To determine the bystander effect of the expression of the HSV tk gene in transfected HNE-1 cells, transfected HNE-1/TK and wild type HNE-1 cells were mixed in the following ratios: 0:1, 1:9, 1:4, 2:3 and 3:2, respectively, and seeded into 96-well plates (3000 cells/well). Cells were treated with 1 mg/ml GCV (a previously tested concentration 5 ) for 96 h under standard cell culture conditions and the relative survival rate was calculated using the MTT assay described above.
STATISTICAL ANALYSIS
All experiments were performed at least three times. Data processing was done by statistical analysis software SPSS ® version 12.0 (SPSS Inc., Chicago, IL, USA). Data are presented as means ± SD. Statistical analysis was performed using a one-way analysis of variance (ANOVA). A P-value of < 0.05 was considered statistically significant.
Results
A 1152 bp fragment was amplified from plasmid PGEM/TK by RT-PCR using the specially designed primers ( Fig.1 ). Digestion of the recombinant plasmid pcDNA3.1(-) CMV.TK with the restriction endonucleases XhoI and HindIII resulted in two fragments: a 5353 bp fragment and a 1141 bp inserted fragment (Fig. 2) , confirming that the recombinant plasmid pcDNA3.1(-)CMV.TK contained the HSV tk gene. 
Suicide gene therapy in nasopharyngeal carcinoma cells
The coding sequence of the HSV tk gene in the recombinant plasmid pcDNA3.1(-) CMV.TK was confirmed by cDNA automatic gene analysis and the result correlated with the appropriate DNA sequence logged in GenBank ® (AF24388[8100986]) ( Fig. 3) .
Successful amplification of the HSV tk gene from the transfected HNE-1/TK cells demonstrated that the HSV tk gene existed in the HNE-1/TK cells. In contrast, the HSV tk gene was not amplified from the wild type HNE-1 cells or the HNE1/(-) cells. Figure 4 shows the expression of the HSV tk gene in the HNE-1/TK cells by the identification of a 410 bp fragment by SDS-PAGE. At the protein level, the expression of HSV tk was confirmed by identification of a 41 kDa protein by Western blotting of HNE-1/TK cells ( Fig. 5 ). HNE-1/TK cells were exposed to a range of concentrations of GCV in order to examine the killing effect of GCV. Cells transfected with the blank plasmid served as controls (Fig. 6) . The relative survival rates of HNE-1/TK cells were 89.13 ± 1.09%, 78.75 ± 2.27%, 69.05 ± 2.38%, 52.75 ± 3.41% and 32.80 ± 1.46% when treated with GCV at the following concentrations: 0.5, 5, 50, 250 and 500 mg/l, respectively; while the relative survival rates were 99.10 ± 1.95%,100.05 ± 0.09%, 101.38 ± 0.02%, 95.15 ± 1.81% and 99.78 ± 1.27% in the control group at these concentrations of GCV. These results demonstrated that GCV at 5, 50, 250 and 500 mg/l killed a significantly (P < 0.05) greater proportion of HNE-1/TK cells than control cells transfected with the blank plasmid. They also show a dose-dependent inhibitory effect of GCV on the growth of HNE-1/TK at concentrations ≥ 0.5 mg/l.
To investigate any bystander effect associated with the expression of HSV tk by 
HNE-1/TK, non-transfected HNE-1 cells were co-cultured with HNE-1/TK cells in varying proportions. As expected, non-transfected cells showed 99.2% viability when not cocultured with HNE-1/TK cells. When HNE-1/TK cells made up 10% of the cell population, 54% of the cells were killed by GCV, indicating a considerable bystander effect (Fig. 7 ).
Discussion
Nasopharyngeal carcinoma is one of the most common malignant tumours in southern China 4 and radiotherapy is currently the most effective treatment in China. Some patients, however, experience continuing problems following therapy because of residual tumour, tumour recurrence or metastasis. The 5-year survival rate in China has been reported to be around 30 -40% for all nasopharyngeal carcinoma patients treated for the first time with radiotherapy. 6 The effectiveness of second or third doses of radiotherapy declines markedly and is very damaging to tissue. In patients receiving a second dose only about 25% show improvement and the 5-year survival rate is only 12 -23%; patients receiving a third dose show no improvement. 7 It is, therefore, clinically important to explore new ways to treat nasopharyngeal carcinoma.
Suicide gene therapy is becoming the most promising area of the relatively new strategy of gene therapy. Many gene therapy studies using the HSV tk/GCV enzyme/prodrug system have been performed during the past 10 years, with satisfactory results. 8 -11 A study by Sa Cunha et al. 10 showed that treatment of tumour-bearing rats with an adenovirus vector Ad.AFPtk and GCV resulted in tumour growth inhibition and cell apoptosis, compared with no effect in untreated tumour-bearing rats or in animals treated with Ad.AFPlacz or buffered saline. Anti-tumour efficacy, based on tumour size and the number of tumours, was demonstrated in more than 50% of the Ad.AFPtk/GCV-treated rats, which was significantly more than the control rats (P < 0.0005). A recent study indicated that the human papillomavirus (HPV) regulatory long control region (LCR) could drive the expression of the tk gene to treat nasopharyngeal carcinoma; around 50 -60% of cells transfected with HPV-11-LCR-TK were killed in the presence of GCV. 12 Furthermore, an in vivo experiment in nude mice transplanted with tumours derived from the transfected nasopharyngeal carcinoma cells showed that GCV treatment resulted in almost complete regression of the transplanted tumour load. 12 Germano et al. 13 reported their preliminary results of a suicide gene therapy in glioblastoma patients whose tumours had recurred after initial conventional radiotherapy or surgical resection. After the ADV.HSVtk complex had been injected into the tumour bed and the patients were treated with GCV, the patients' Karnofsky score was maintained ≥ 70 in 80% and 55% of patients at 3 and 6 months, respectively. Furthermore, the survival time of the ADV.HSVtk complex-treated patients was prolonged to an average of 112.3 weeks. These studies have demonstrated that the HSV tk/GCV system is an effective strategy to treat some tumours, although the strategy was not effective in pancreatic cancer evaluated in vivo in a mouse model. 14 In the present study, a plasmid containing HSV tk was constructed to investigate if the HSV tk/GCV system could kill nasopharyngeal carcinoma cells in vitro. The plasmid pcDNA3.1(-)CMV was chosen to be the plasmid vector because: (i) it is safer than a viral vector; (ii) it is not associated with immunogenicity; (iii) the molecular biology is straightforward because the plasmid is only 5.4 kb and the inserted HSV tk fragment was less than 2 kb; (iv) it is universally accepted that plasmids are the best type of vector for inserting sequences < 10 kb and they have a large capacity; and (v) the cytomegalovirus (CMV) promoter drives the highly effective expression of inserted foreign genes. We subcloned the HSV tk gene into the plasmid pcDNA3.1(-)CMV to construct the recombinant plasmid pcDNA3.1(-)CMV.TK, in which the expression of the HSV tk gene was driven by the CMV promoter. Automatic gene analysis verified that the HSV tk gene had been inserted into the empty plasmid successfully and the translation and expression of the HSV tk gene were unaffected.
In this study, electroporation was considered to be a superior method of transfection than lipofection for transfecting the HNE-1 cells in order to establish HSV tkexpressing cell clones. 15, 16 We showed that the growth of HNE-1/TK cells was inhibited in a dose-dependent manner by treatment with GCV. We also demonstrated a considerable bystander effect. For example, even when only 10% of the cultured cells expressed HSV tk, 54% of the co-cultured cells were killed by treatment with GCV.
In order to enhance the killing effect on tumours, strategies for specifically targeting gene therapies have been performed in which the expression of the HSV tk gene in tumour cells has been selectively driven by special gene promoters, such as alpha-fetoprotein, carcinoembryonic antigen, prostate-specific antigen and human telomerase reverse transcriptase promoter. As a result, the HSV tk gene is only expressed in the targeted tumour cells and not in the normal cells, so that tumour cells are killed and non-tumour cells remained unaffected. 17 -19 Another problem encountered by gene therapy is the efficiency of transfer of genetic material to mammalian cells. Several studies have attempted to improve the transfection efficiency of HSV tk into tumour cells using the transduction of HSV-1 VP22 protein, which enters cells with high efficiency, increasing the cytotoxic effect of the HSV tk/GCV system. 20 -23 A new method of gene therapy might be achieved using VP22 protein in combination with tissue-specific promoters that only drive the expression of the targeted genes (such as HSV tk) in nasopharyngeal carcinoma cells. We plan to investigate this new strategy further.
